Navigation Links
FDA funds pediatric trial testing genetically reprogrammed HSV to treat cancer
Date:10/12/2010

CINCINNATI A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S. Food and Drug Administration grant to support the research.

The Phase I trial at Cincinnati Children's Hospital Medical Center currently focuses on testing the safety of the agent HSV1716 in patients. The study includes young patients with solid tumors such as rhabdomyosarcoma or Ewing's sarcoma. These cancers have limited treatment options and survival rates under 30 percent when the cancers recur and spread to other parts of the body.

Survival curves for stubborn, metastatic childhood cancers have leveled off in the last decade, underscoring the need for new therapeutic approaches, says Timothy Cripe, M.D., Ph.D., principal investigator on the trial and a physician/researcher in division of Hematology/Oncology at Cincinnati Children's.

"We've exhausted our ability to improve cure rates with existing conventional therapies and we need new solutions," he said. "This is why we are testing HSV. It's a potent virus that has been manipulated genetically with the intent of making it safe for the patient. When you're trying to fight fire with fire you need something that is strong."

The $600,000 grant from FDA is part of a program encouraging clinical development of "orphan drugs" as new treatments for rare diseases or conditions. The HSV1716 virus being tested in this trial was developed by Crusade Laboratories of Glasgow, Scotland.

HSV1716 is similar to other viruses now under development by Dr. Cripe and colleagues at Cincinnati Children's in that certain genes are removed so the virus does not infect healthy dormant cells or cause the disease in the recipient. Instead, the genetic manipulation is designed to prompt the virus to target, infect and degrade only rapidly dividing cancer cells.

Genetic information also can be added to HSV that programs the virus
'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. NIH funds Center of Excellence for Molecular Hematology at Cincinnati Childrens
2. $1.5M grant funds research aimed at reducing strokes in children with sickle cell disease
3. NIH funds center at Arizona State to battle infectious diseases
4. French national research agency funds PREDIMOL project
5. NHGRI funds development of third generation DNA sequencing technologies
6. $22.5 million grant funds international study of membrane proteins
7. NSF funds innovative approach to biomimetic nanofiber bone regeneration
8. Gulf oil spill: NSF funds research on impacts to Florida Everglades
9. NSF funds Virginia Tech program to train researchers at intersection of engineering, biology
10. NIH funds multicenter glue grant to study enzyme function
11. California funds UCI basic research on stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative ... cut emergency room wait times by an average of ... Center, according to a recent study published in the ... using the suite to access data from incoming patients, ... "Using Geneva,s technology platform we have been able ...
(Date:7/24/2014)... average over a 35 year period in which the ... of humans on declining animal numbers. This decline matters ... spiders, crustaceans, slugs and worms bring to our day-to-day ... for nutrient cycling, water filtration and human health. , ... by UCL, Stanford and UCSB, focused on the demise ...
(Date:7/24/2014)... a smog-free Los Angeles, where electric cars ply silent ... on heat from beneath the earth, from howling winds ... Stanford study finds that it is technically and economically ... powered by clean, renewable energy. Published in Energy ... inexpensive and reliable energy supply in California that could ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... of Medicine has helped confirm the reliability of a ... the long-promised era of personalized medicine based on each ... the five sites that helped determine that the genetic ... developing cirrhosis from chronic hepatitis C infection. That means ...
... has shown that opening windows and doors provided ventilation ... and 18 times that of rooms with windows and ... Escombe from Imperial College London, compared the airflow in ... rooms, TB wards, respiratory wards, general medical wards, outpatient ...
... lupus, is a complex autoimmune disease marked by ... among other symptoms. Some studies have described a ... psychosis, and a protein autoantibody associated with the ... To investigate how an autoantibody could stimulate behavioral ...
Cached Biology News:New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3New insights into autoimmunity and depression 2
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, LLC ... with University College Hospital (UCH) Ibadan Board ... project to finance, design, construct, and operate and maintain ... Nigeria . Under the first of the 4-phase ... documents and funding applications. UCH Ibadan intends to finance ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... -- Research and Markets has announced the ... report to their offering.  ... in vitro growth of plant or animal cells for ... production. Cell culture is a crucial step in tissue ... culture consumables are necessary for the in vitro production ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Adult Cough Products Using ... Technologies, CHESTER, N.J. and SALT LAKE CITY, Sept. ... and Lipocine Inc., a,privately- held, leading drug delivery company ... drug delivery and,therapeutics needs, today announced that they have ...
... Company Enters Into License, Commercialization and Supply Agreement, Company to Host Conference ... ... 2007, LEXINGTON, Mass., Sept. 19 ... AGN ), through its acquisition of Esprit Pharma, has obtained the,United States ...
... Kleiner Perkins ... Strong Endorsement of Technology Pioneer at Forefront of Developing No- ... Compromise Biofuels, ... hydrocarbon biofuels, today,announced that it closed the first tranche of its $70 million ...
Cached Biology Technology:Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 2Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 3Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6Amyris Biotechnologies Announces $70 Million Series B Round 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: